logo

RGC

Regencell Bioscience·NASDAQ
--
--(--)
--
--(--)
0.90 / 10
Underperform

RGC's fundamental profile is concerning, with a weak score of 0.9/10. Key red flags include a high Days Sales Outstanding of 313.9140, indicating slow receivable collection, and a Total Operating Revenue YoY growth rate of 45.9666, which, despite its positive value, ranks in the highest quartile and historically correlates with negative returns. The stock also has no revenue and recurring losses, and it is under a Justice Department investigation, all of which contribute to an underperform rating and a cautious investment stance.

Fundamental(0.9)SentimentTechnical

Analysis Checks(2/4)

Total operating revenue (YoY growth rate %)
Value45.97
Score0/3
Weight70.23%
1M Return-6.11%
Days sales outstanding
Value313.91
Score1/3
Weight20.87%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight15.15%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value64.40
Score2/3
Weight-6.25%
1M Return0.43%
Is RGC undervalued or overvalued?
  • RGC scores 0.90/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.81% ROE, 0.00% net margin, -3293.10 P/E ratio, 2770.41 P/B ratio, and 17.24% earnings growth, these metrics solidify its Underperform investment rating.